A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies
Inclusion Criteria:
- Measurable disease
- Life expectancy of at least 3 months
- Must have at least one prior chemotherapy containing a platinum
Exclusion Criteria:
- Known or documented brain metastases
- Prior cetuximab therapy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety and efficacy of the combination of Tarceva and Erbitux
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA225-101
NCT ID:
NCT00207077
Start Date:
August 2005
Completion Date:
May 2007
Related Keywords:
- Neoplasms
- Advanced Solid Tumors
- Neoplasms
Name | Location |
|---|---|
| Christiana Care Health Services, Inc. | Newark, Delaware 19718 |
